Qilong Zhang

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 476 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Aditya Bardia, Komal Jhaveri, S-A. Im et al. · Annals of Oncology · 2023 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study

Lei Yang, Xiaoxuan Sun, Shu-Kui Qin et al. · European Journal of Cancer Care · 2017 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16

LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial

Binghe Xu, Qilong Zhang, Ping Zhang et al. · Annals of Oncology · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Prediction of prognosis and immunotherapy response in lung adenocarcinoma based on CD79A, DKK1 and VEGFC

Qilong Zhang, Mingyuan Zhao, Shuangyan Lin et al. · Heliyon · 2023 · 10 citations · Full text

Medicine, Immunology, Oncology +17